Business
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":" LOS ANGELES--(BUSINESS WIRE)--\nChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made an impact on their industries and society at large.\n\n\nThis recognition underscores ChromaDex's industry-leading NAD+ research and its expanding portfolio of healthy aging products featuring Niagen® (patented nicotinamide riboside or NR), the most efficient and high-quality NAD+ precursor. Such products include the direct-to-consumer dietary supplement, Tru Niagen®, and the newly unveiled pharmaceutical-grade Niagen IV.\n\n\n“Our mission is to help people around the world to age better, and this honor reflects the progress we’re making toward achieving that goal,” said ChromaDex CEO and Founder of Tru Niagen, Rob Fried.\n\n\nThe Inc. Best in Business list recognizes companies that, through exceptional execution, have achieved significant milestones and core business wins. Best in Business can be found online at inc.com/best-in-business and will be in the upcoming winter print edition of Inc. magazine.\n\n\n“For over 40 years Inc. has been committed to recognizing America’s most dynamic businesses and honoring the great work they do. These businesses have had a profound impact on their industries, solving important problems, and shaping the future of business in ways that will have lasting effects,” says Inc. editor-in-chief Mike Hofman.\n\n\nFor additional information on ChromaDex and the science behind Niagen, please visit www.chromadex.com.\n\n\nForward-Looking Statements:\n\n\nThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to product development. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as \"expects,\" \"anticipates,\" \"intends,\" \"estimates,\" \"plans,\" \"potential,\" \"possible,\" \"probable,\" \"believes,\" \"seeks,\" \"may,\" \"will,\" \"should,\" \"could\" or the negative of such terms or other similar expressions. Risks that contri...